UNASSIGNED: Modern-day stenting procedures leverage advances in pharmacotherapy and device innovation. @entity1 treated with contemporary antiplatelet agents, peri-procedural @entity5582 therapy and new-generation drug-eluting stents (DES) have excellent outcomes over the short to medium term. Indeed, coupled with the reducing costs of these devices in most countries there remain very few indications where @entity1 should be denied treatment with standard-of-care DES therapy. The two major causes of stent failure are stent @entity715 (ST) and in-stent @entity256 (ISR). The incidence of both has reduced considerably in recent years. Current clinical registries and randomized trials with broad inclusion criteria show rates of ST at or <1% after 1 year and    0.2-0.4% per year thereafter; rates of clinical ISR are 5% respectively. Angiographic surveillance studies in large cohorts show rates of angiographic ISR of    10% with new-generation DES. The advent of high-resolution intracoronary imaging has shown that in many cases of late stent failure neoatherosclerotic change within the stented segment represents a final common pathway for both @entity715 and restenotic events. In future, a better understanding of the pathogenesis of this process may translate into improved late outcomes. Moreover, the predominance of non-stent-related disease as a cause of subsequent @entity583 during follow-up highlights the importance of lifestyle and pharmacological interventions targeted at modification of the underlying disease process. Finally, although recent developments focus on strategies which circumvent the need for chronically indwelling stents-such as @entity8038 or fully bioresorbable stents-more data are needed before the wider use of these therapies can be advocated.

Stent @entity715 and XXXX : what have we learned and where are we going? The Andreas Gr  ntzig Lecture ESC 2014.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity8038 :: ('MESH:D058456', 'Disease') :: ['drug-coated balloons'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic'] @entity5582 :: ('462', 'Gene') :: ['antithrombin']
@entity256 :: (MESH:D023903,Disease) :: ['restenosis']
